ACETYLSALICYLIC ACID IN CARDIOLOGY: BENEFITS, RISKS, AND CLINICAL INDICATIONS

ACETYLSALICYLIC ACID IN CARDIOLOGY: BENEFITS, RISKS, AND CLINICAL INDICATIONS

Acetylsalicylic acid (ASA) is an antiplatelet agent widely used in cardiology and has an essential role in the prevention and treatment of cardiovascular diseases. By irreversibly inhibiting cyclooxygenase-1 (COX-1), ASA reduces platelet aggregation and the risk of thrombotic events, being recommend...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ciprian Adrian Dinu, Alina Mihaela Elisei, Daniela Mihalache, Denisa Marin Batir
Format:	Article
Language:	English
Published:	Romanian Society of Oral Rehabilitation 2025-03-01
Series:	Romanian Journal of Oral Rehabilitation
Subjects:	acetylsalicylic acid cardiology cardiovascular prevention acute coronary syndromes antiplatelet therapy hemorrhagic risks
Online Access:	https://rjor.ro/acetylsalicylic-acid-in-cardiology-benefits-risks-and-clinical-indications/
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

ON THE 125TH ANNIVERSARY OF ACETYLSALICYLIC ACID
by: I. N. Bokarev, et al.
Published: (2016-01-01)

ANNUAL CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY: NEW TRIALS, NEW GUIDELINES
by: S. Y. Martsevich, et al.
Published: (2015-10-01)

The resolution of the Expert Council on current issues of the use of acetylsalicylic acid for the purpose of primary prevention of cardiovascular diseases in the light of new scientific data and updated clinical guidelines
by: O. M. Drapkina, et al.
Published: (2023-01-01)

A Prospective, Initiative, Single-Center Open Post-Registration Comparative Study of Laboratory Efficacy of Various Forms of Acetylsalicylic Acid in a Cardioprotective Dose with Different Composition of Excipients: Results of the SFAIROS Study
by: N. V. Lomakin, et al.
Published: (2020-07-01)

Clinical pharmacology of acetylsalicylic acid as an anti-thrombotic agent
by: V. V. Rafalsky, et al.
Published: (1970-01-01)

EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: A. L. Alyavi, et al.
Published: (2016-01-01)

Aspirin in the Modern Era of Cardiovascular Disease Prevention
by: Ella Murphy, et al.
Published: (2021-09-01)

Current approaches to the selection of acetylsalicylic acid dosage forms in cardiology
by: S. R. Gilyarevskiy, et al.
Published: (2022-06-01)

Compliance as the major effectiveness determinant in preventive acetylsalicylic acid therapy
by: V. V. Rafalskiy, et al.
Published: (2011-04-01)

ACETYLSALICYLIC ACID: DO WE KNOW EVERYTHING ABOUT IT AND ITS PROPER USE?
by: S. A. Boldueva, et al.
Published: (2015-12-01)

LOW DOSAGE ACETYLSALICYLIC ACID: A VARIETY OF FORMULATIONS
by: V. V. Rafalsky, et al.
Published: (2017-08-01)

ACETYLSALICYLIC ACID: CONTROVERSIAL AND OUTSTANDING ISSUES
by: E. N. Dankovtseva
Published: (2015-09-01)

RESISTANCE TO ACETYLSALICYLIC ACID AND PREVALENCE OF THROMBOSIS IN PATIENTS WITH STABLE ANGINA
by: N. F. Putchinyan, et al.
Published: (2015-12-01)

ACETYLSALICYLIC ACID IN RHEUMATOLOGY: NEW EVIDENCE
by: Yuri Vladimirovich Muravyev, et al.
Published: (2013-12-01)

ACETYLSALICYLIC ACID IN PRIMARY AND SECONDARY PREVENTION OF STROKE
by: P. S. Laguta
Published: (2017-05-01)

ACETYLSALICYLIC ACID: WHAT'S NEW IN THE OLD DRUG?
by: I. V. Zhirov
Published: (2015-12-01)

LONG-TERM THERAPY WITH ACETYLSALICYLIC ACID. HOW TO AVOID THE POSSIBLE COMPLICATIONS?
by: I. V. Zhirov
Published: (2016-01-01)

Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk
by: O. V. Averkov
Published: (2021-02-01)

Pepsinogen I as a marker of risk of gastric mucosal cell destruction in Helicobacter pylori-infected patients taking acetylsalicylic acid
by: I.G. Paliy, et al.
Published: (2025-06-01)

Zyllt and acetylsalicylic acid in coronary atherosclerosis patients after coronary artery bypass graft intervention. Main results of the ZEUS Study: medication effectiveness, acetylsalicylic acid resistance mechanisms, short and long-term clinical outcomes
by: Yu. I. Grinstein, et al.
Published: (2009-08-01)

SOME ASPECTS OF IMPROVING ADHERENCE TO DUAL ANTITHROMBOTIC THERAPY AFTER ACUTE CORONARY SYNDROME
by: A. D. Erlikh
Published: (2017-05-01)

Acetylsalicylic acid in primary prevention among patients with arterial hypertension
by: A. V. Melekhov, et al.
Published: (2013-10-01)

Study of pharmaceutical properties of low-dosage enteric-coated acetylsalicylic acid
by: V. V. Rafalsky, et al.
Published: (2016-02-01)

Antithrombotic effect of different acetylsalicylic acid drug formulations: is there a difference?
by: A. V. Sidorov
Published: (2021-11-01)

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: D. H. Aynetdinova, et al.
Published: (2015-12-01)

Acetylsalicylic acid as an anti-platelet agent: what forms should be used, according to evidence-based medicine?
by: O. V. Averkov
Published: (2010-04-01)

Incidence and prognosis of first-ever intracerebral hemorrhage on antiplatelet therapy over 10 years in a population-based stroke registry
by: Matteo Foschi, et al.
Published: (2024-11-01)

Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025
by: Maciej Banach, et al.
Published: (2025-01-01)

COMBINED ACETYLSALICYLIC ACID TABLETS TECHNOLOGY
by: A. V. Simonyan, et al.
Published: (2019-01-01)

ACETYLSALICYLIC ACID IN THE PREVENTION OF ATHEROTHROMBOTIC EVENTS
by: A. V. Govorin, et al.
Published: (2015-12-01)

SYNTHESIS, ANTIAGGREGATION AND ANTITROMBOTIC ACTIVITIES OF NEW DERIVATIVES OF HYDROXYBENZOIC ACIDS WITH TAURIC FRAGMENT
by: A. K. Brel, et al.
Published: (2021-08-01)

HEMOSTASIS AND FUNCTIONAL PROPERTIES OF NEUTROPHILS IN PATIENTS WITH VARIOUS SENSITIVITY TO ACETYLSALICYLIC ACID IN ACUTE CORONARY SYNDROME
by: I. Yu. Grinshtein, et al.
Published: (2015-10-01)

Features of the Hemostasis and Platelets Enzyme Activity in Patients with Different Sensitivity to Acetylsalicylic Acid by the Acute Coronary Syndrome
by: I. Yu. Grinshtein, et al.
Published: (2016-11-01)

EFFICACY AND SAFETY OF ACETYLSALICYLIC ACID IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES
by: S. N. Tolpygina, et al.
Published: (2015-12-01)

ANTIPLATELET THERAPY IN PROPHILAXY OF NEGATIVE CARDIOVASCULAR EVENTS AFTER CORONARY REVASCULARIZATION. IS THERE A CONSENSUS?
by: Yu. I. Grinschtein, et al.
Published: (2014-06-01)

GASTROENTEROPATHIES ASSOCIATED WITH ACETYLSALICYLIC ACID: HOW TO IMPROVE SAFETY OF THERAPY
by: A. L. Komarov
Published: (2016-01-01)

Postgenomic aspects of resistance to acetylsalicylic acid in patients with coronary artery disease
by: Yu. I. Grinshtein, et al.
Published: (2024-11-01)

ACETYLSALICYLIC ACID IN LOW DOSES FOR SECONDARY PREVENTION OF CARDIO-VASCULAR COMPLICATIONS
by: N. A. Dmitrieva, et al.
Published: (2016-01-01)

ACETYLSALICYLIC ACID AND PREVENTION OF FATAL OUTCOMES IN CARDIOVASCULAR DISEASE: SELECTING MEDICATION FORM AND DOSE
by: O. V. Averkov
Published: (2012-08-01)

Platelet reactivity clinical and biochemical markers when taking acetylsalicylic acid as part of dual antiplatelet therapy in the myocardial infarction subacute period
by: T. P. Pronko, et al.
Published: (2025-01-01)